Antiarrhythmic effect of bisoprolol, a highly selective β 1-blocker, in patients with paroxysmal atrial fibrillation

International Heart Journal

Volumn 49, Issue 3, 2008, Pages 281-293

  Ishiguro, Haruhisa ^a   Ikeda, Takanori ^a   Abe, Atsuko ^a   Tsukada, Takehiro ^a   Mera, Hisaaki ^a   Nakamura, Kentaro ^a   Yusu, Satoru ^a   Yoshino, Hideaki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

blocker; Antiarrhythmic effect; Paroxysmal atrial fibrillation; Sympathetic nerve

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CIBENZOLINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; PILSICAINIDE; PROPAFENONE; WARFARIN;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; CIRCADIAN RHYTHM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FEMALE; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL SIGNIFICANCE; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BISOPROLOL; CIRCADIAN RHYTHM; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME;

EID: 49449089384     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.281     Document Type: Article

References (24)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commitee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
2. JCS 2004 Guidelines for the Drug Treatment of Arrhythmias: a report of the Japanese Circulation Society Committee for Diagnosis and Treatment of Cardiovascular Diseases. Circ J 2004; 68 (Suppl. IV), 981-1053. (Japanese)
3. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
4. Lindemann JP, Watanabe AM. Sympathetic control of cardiac electrical activity, In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: Saunder; 1990: 277-83.
5. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90: 1765-73.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, Lancet 1999; 353: 9-13.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
9. Wellstein A, Palm D, Belz GG; Butzer R, Polsak R, Pett B. Reduction of exercise tachaycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. Eur Heart J 1987 (Suppl); 8: 3-8.
10. Yamashita T, Kumagai K, Koretsune Y, et al. A new method for evaluationg quality of life specific to patients with atrial fibrillation: Atrial Fibrillation Quality of Life Questionnaire (AFQLQ). Jpn J Electrocardiol 2003; 23: 332-43. (Japanese)
11. Yamashita T, Ogawa S, Aizawa Y, et al. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 2003; 67: 738-41.
12. Page RL, Wilkinson WE, Clair WK, McCarthy EA, Pritchett EL. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89: 224-7.
13. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
14. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20: 527-32.
15. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28: 1458-63.
16. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. The Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Circulation 1997; 96: 2625-32.
17. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
18. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997; 96: 2455-61.
19. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007; 28: 457-62.
20. Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after onpump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 2007; 4: 1170-4.
21. Kühlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36: 139-46.
22. Steeds RP, Birchall AS, Smith M, Channer KS. Ah open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999; 82: 170-5.
23. Plewan A, Lehmann G, Ndrepepa G, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 2001; 22: 1504-10.
24. Singh BN. β-blockers and calcium channel blockers as antiarrhythmic drugs. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia: Saunders; 2004: 918-31.